RLMD
Relmada Therapeutics Inc
$
0.588
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.588
Open
0.588
VWAP
0.59
Vol
20.47K
Mkt Cap
19.52M
Low
0.588
Amount
12.04K
EV/EBITDA(TTM)
--
Total Shares
30.17M
EV
-1.10M
EV/OCF(TTM)
--
P/S(TTM)
--
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Show More
2 Analyst Rating
70.07% Upside
Wall Street analysts forecast RLMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLMD is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
70.07% Upside
Current: 0.588
Low
1.00
Averages
1.00
High
1.00
70.07% Upside
Current: 0.588
Low
1.00
Averages
1.00
High
1.00
Mizuho
Uy Ear
Buy
to
Hold
Downgrades
$23 → $1
2024-12-05
Reason
Mizuho
Uy Ear
Price Target
$23 → $1
2024-12-05
Downgrades
Buy
to
Hold
Reason
Mizuho analyst Uy Ear downgraded Relmada Therapeutics to Neutral from Outperform with a price target of $1, down from $23. The Data Monitoring Committee finding of futility is "truly disappointing and likely means the end of the line" for REL-1017 in major depressive disorder, says the analyst, who removes the firm's sales forecast, with a previous peak sales assumption of $1.7B, and corresponding spending assumptions related to REL-1017 from the firm's model. Relmada has a second asset, REL-P11, which is low-dose, modified-release psilocybin formulation to treat metabolic diseases, but REL-1017 was "clearly the more important asset," the analyst added.
Leerink Partners
Marc Goodman
Buy
to
Hold
Downgrades
$10 → $1
2024-12-04
Reason
Leerink Partners
Marc Goodman
Price Target
$10 → $1
2024-12-04
Downgrades
Buy
to
Hold
Reason
Leerink analyst Marc Goodman downgraded Relmada Therapeutics to Market Perform from Outperform with a price target of $1, down from $10, after the company announced that the pre-planned interim analysis of Reliance II, conducted by the Independent Data Monitoring Committee, indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance. The firm, which has removed REL-1017 revenues from its model and have added nominal revenues for RELP11 starting in 2032 while awaiting additional data, tells investors that based on today's news "it makes sense to move to the sidelines."
Jefferies
Andrew Tsai
Hold
to
Strong Buy
Upgrades
$3.5 → $13
2024-09-17
Reason
Jefferies
Andrew Tsai
Price Target
$3.5 → $13
2024-09-17
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Relmada Therapeutics Inc (RLMD.O) is -0.31, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Relmada Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.99
Current PE
-0.31
Overvalued PE
0.34
Undervalued PE
-6.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.43
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.68
Undervalued EV/EBITDA
-3.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.01
Current PS
0.00
Overvalued PS
0.04
Undervalued PS
-0.02
Financials
Annual
Quarterly
FY2025Q2
YoY :
-45.69%
-10.22M
Operating Profit
FY2025Q2
YoY :
-44.47%
-9.87M
Net Income after Tax
FY2025Q2
YoY :
-49.15%
-0.30
EPS - Diluted
FY2025Q2
YoY :
-51.73%
-6.40M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
8
461.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
8
642.9K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
8
461.3K
USD
Months
6-9
0
0.0
USD
Months
0-12
8
642.9K
USD
Months
RLMD News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:08:13
Relmada Therapeutics appoints Lotan to Chair of Clinical Advisory Board
2025-06-17 (ET)
2025-06-17
07:03:54
Relmada Therapeutics appoints Raj Pruthi as CMO, Urology
2025-05-15 (ET)
2025-05-15
14:49:05
VA secretary wants to find answers on psychedelics therapies, Politico says
Sign Up For More Events
Sign Up For More Events
News
5.0
08-08SeekingAlphaRelmada outlines 2026 trial launches for NDV-01 and sepranolone as pipeline advances
9.5
07-22BenzingaWhy Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
5.0
07-15NewsfilterRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Sign Up For More News
People Also Watch
ADGM
Adagio Medical Holdings Inc
1.285
USD
0.00%
IVDA
Iveda Solutions Inc
1.794
USD
0.00%
CSCI
COSCIENS Biopharma Inc
3.560
USD
0.00%
MNDR
Mobile-health Network Solutions
0.898
USD
+0.90%
YQ
17 Education & Technology Group Inc
1.950
USD
0.00%
SGLY
Singularity Future Technology Ltd
0.990
USD
0.00%
BCLI
Brainstorm Cell Therapeutics Inc
0.672
USD
-2.56%
ASTC
Astrotech Corp
5.300
USD
0.00%
FAQ
What is Relmada Therapeutics Inc (RLMD) stock price today?
The current price of RLMD is 0.588 USD — it has increased 0 % in the last trading day.
What is Relmada Therapeutics Inc (RLMD)'s business?
What is the price predicton of RLMD Stock?
What is Relmada Therapeutics Inc (RLMD)'s revenue for the last quarter?
What is Relmada Therapeutics Inc (RLMD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Relmada Therapeutics Inc (RLMD)'s fundamentals?
How many employees does Relmada Therapeutics Inc (RLMD). have?